RE:RE:RE:More about Dr. Stephan and Neubase TherapeuticsAs I mentioned in my last post a big number of share out, doesn't necessary mean that a company will not succeed.
Having said that... The advantage of having a low number of shares out, is that on good news the SP could go up faster.
Nailbiter1...You are right when you said it is very important to keep a watchful eye on OHRP:US.
OHRP:US = Share out..2.8 million(a ridiculously low number of share).
If Dietrich Stephan (Holy-Grail of cancer tests) pull out a rabbit from his hat... OHRP:US SP could go ballistic very, very fast.
Ok guy no more Dietrich Stephan for me.
Nailbiter1 wrote: Here is why it is very important to keep a watchful eye on NeuBase / OHRP. In Jan 2019 there was questioning about the merger with Dr. Stephan's company. Then OHRP went through a monumental 20 - 1 reverse split to maintain SP compliance with NASDAQ. Historically, these big splits have trouble surviving the first three years. If Stephan can hold all this weight solely on his shoulders, it is a testament to his brilliance and the importance of his company. Put OHRP on your watchlist and keep an eye on it...
Ohr Pharmaceutical, Inc. (OHR) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed merger of OHR with NeuBase Therapeutics, Inc. The Ohr merger investigation concerns whether the Board of Ohr breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether NeuBase Therapeutics, Inc. is underpaying for Ohr shares, thus unlawfully harming Ohr shareholders.
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Ohr or the Company) (Nasdaq: OHRP) announced today that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 per share. The Company's stockholders approved the reverse stock split at the Company's special meeting of shareholders held on January 18, 2019. The Company's common stock is expected to commence trading on a post-reverse stock split basis on February 4, 2019. This reverse stock split will help us maintain our NASDAQ listing while we move forward with the process to complete our previously announced merger with NeuBase Therapeutics, said Jason Slakter, M.D., chief executive officer of Ohr Pharmaceutical. NeuBases next generation gene silencing platform has broad therapeutic potential, and we believe the proposed merger provides an excellent opportunity to create value for our stockholders with a science-driven company working to transform the paradigm for treating rare genetic diseases. The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market and does not have an impact on the proposed share allocation for the planned merger with NeuBase.
NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The NASDAQ Capital Market. Accordingly, the Company has regained compliance with the Bid Price Rule and NASDAQ considers the matter closed
Northerencents wrote: Quite the guy to have on our side especially being linked with the venture fund really makes me wonder what kind of shark eyes we might already be being watched by